Phase 1/2 Immunology & Autoimmune Deal Benchmarks
Market Analysis
Phase 1/2 immunology & autoimmune licensing deals carry a median total deal value of $1.9B, with upfront payments ranging from $139M to $427M. At this stage, deal structures are heavily milestone-weighted, reflecting the significant clinical risk ahead. The recommended split allocates 15% to upfront and 85% to milestones.
The immunology & autoimmune landscape at the phase 1/2 stage is characterized by high competitive intensity, particularly in inflammatory bowel disease and autoimmune conditions. Development milestones average $440M, regulatory milestones contribute $551M, and commercial milestones reach $598M. CAR-T for autoimmune diseases, TL1A inhibitors, and next-generation targeted therapies are reshaping the licensing landscape.
Royalty rates for phase 1/2 immunology & autoimmune deals range from 10.9% to 18.6% at the base tier, with high-tier escalation to 22.6%. Earlier-stage royalties are at the lower end of industry ranges, reflecting higher clinical risk.
Full Benchmark Analysis
Complete deal term ranges, comparable transactions, and negotiation insights.
Start 7-Day Free Trial$299/mo after trial · Cancel anytime
Customize these benchmarks for your asset
Adjust phase, modality, competitive position, and 10+ other parameters.
Frequently Asked Questions
What is the average upfront payment for phase 1/2 immunology & autoimmune deals?
How are phase 1/2 immunology & autoimmune deal milestones structured?
What royalty rates are typical for phase 1/2 immunology & autoimmune licensing?
Full Benchmark Analysis
Complete deal term ranges, comparable transactions, and negotiation insights.
Start 7-Day Free Trial$299/mo after trial · Cancel anytime
Ready to Calculate Your Deal Terms?
Get instant, customized benchmarks based on real market data from 1,600+ biopharma licensing deals.
Start CalculatingNeed the full deal landscape?
The Deal Intelligence Brief covers every modality and deal structure for this indication — 52 deal calculations, AI strategic narrative, comparable transactions, partner matching, and white-label branding. Delivered in 24 hours.